Real-World Effectiveness of Guselkumab for Induction of Remission in Crohn’s Disease: A Prospective Multicentre Cohort Study with Propensity Score-Matched Comparison to Risankizumab

Authors:

Abstract
Background: No head-to-head trials compare selective interleukin-23 inhibitors in Crohn’s disease (CD), leaving clinicians without direct evidence to guide treatment selection. We aimed to evaluate real-world induction effectiveness of guselkumab in CD and perform propensity score-matched (PSM) comparisons against risankizumab. Methods: This prospective multicentre study included adults with moderate-to-severe CD initiating guselkumab in the United Arab Emirates. The primary outcome was clinical remission at Week 12 (Harvey-Bradshaw Index 0.9) and clinical response (86% vs 87%, p = 0.87) between guselkumab and risankizumab, with no significant between-group biomarker differences. Conclusions: Guselkumab demonstrated robust real-world induction effectiveness comparable to risankizumab across clinical and biochemical outcomes. These findings warrant confirmation in larger, longer-term comparative studies with endoscopic endpoints.

This publication has 24 references indexed in Scilit: